肝性脳症市場 - 競合情勢

2024年には、GlobalDataの肝性脳症に関する疫学予測でカバーされている16カ国において、450万人以上の診断された肝性脳症の有病例が予測されています。現在、HE治療薬として承認されている新薬は1品目です。

HEの研究開発活動は緩やかで、パイプラインには12分子が存在しますが、そのうち第III相は1剤のみ、第II相は6剤です。

米国は、HEの臨床試験を実施する主要国として台頭してきています。過去10年間、北米ではパートナーシップとライセンシング契約が主流でした。

当レポートでは、世界の肝性脳症市場について調査し、疾患の概要とともに、治験動向、パイプライン概要、将来の見通しなどを提供しています。

目次

第1章 目次

第1章 序文

第2章 主な調査結果

第3章 病気の情勢

• 疾患概要
• 疫学概要
• 治療概要

第4章 上市済み薬剤の評価

• 主な上市済み薬剤
• 作用機序別概要
• 分子タイプ別概要
• 製品プロファイルと売上予測

第5章 価格設定と償還評価

• 年間治療費
• 価格設定と償還までの時間

第6章 パイプライン薬剤の評価

• 中期から後期段階のパイプライン薬剤
• 開発段階別概要
• 作用機序別概要
• 分子タイプ別概要
• 薬剤固有の相転移成功率（PTSR）と承認可能性（LoA）
• 治療領域と適応症別のPTSRとLoA

第7章 臨床試験の評価

• 歴史的概要
• 相別概要
• ステータス別概要
• 進行中および計画中の試験の相別概要
• 仮想コンポーネントを使用した治験
• 地理的概要
• 地域別の単一国および多国籍試験
• 上位20のスポンサーと相別内訳
• 上位20のスポンサーのステータス別内訳
• エンドポイントステータス別概要
• 人種および民族別の概要
• 登録データ
• 治験サイトの上位20か国
• 世界のトップ20サイト
• 実現可能性分析- 地理的概要
• 実現可能性分析- ベンチマークモデル

第8章 取引の情勢

第9章 商業的評価

• 主要な市場参入企業

第10章 将来の市場促進要因

第11章 付録

This reports provides a data-driven overview of the current and future competitive landscape in Hepatic Encephalopathy therapeutics.

• In 2024, more than 4.5 million diagnosed prevalent cases of HE are anticipated in the 16 countries covered in GlobalData's epidemiology forecast for HE.
• Currently, there is a single approved innovator drug available in the market for HE.
• R&D activities for HE are moderate with 12 molecules in the pipeline, out of which Phase III holds only one drug, whereas Phase II holds six drugs.
• The US is emerging as the key country for conducting HE trials.
• During the past decade, partnerships and licensing agreements were the predominant deal types in North America.

Scope

GlobalData's Hepatic Encephalopathy: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Hepatic Encephalopathy market.
• Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Hepatic Encephalopathy market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1 Table of Contents (PowerPoint Deck)

1 Preface

• 1.1 Contents
• 1.2 Report Scope
• 1.3 List of Tables and Figures
• 1.4 Abbreviations

2 Key Findings

3 Disease Landscape

• 3.1 Disease Overview
• 3.2 Epidemiology Overview
• 3.3 Treatment Overview

4 Marketed Drugs Assessment

• 4.1 Leading Marketed Drugs
• 4.2 Overview by Mechanism of Action
• 4.3 Overview by Molecule Type
• 4.4 Product Profiles and Sales Forecast

5 Pricing and Reimbursement Assessment

• 5.1 Annual Cost of Therapy
• 5.2 Time to Pricing and Reimbursement

6 Pipeline Drugs Assessment

• 6.1 Mid-to-late-stage Pipeline Drugs
• 6.2 Overview by Development Stage
• 6.3 Overview by Mechanism of Action
• 6.4 Overview by Molecule Type
• 6.5 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
• 6.6 Therapy Area and Indication-specific PTSR and LoA

7 Clinical Trials Assessment

• 7.1 Historical Overview
• 7.2 Overview by Phase
• 7.3 Overview by Status
• 7.4 Overview by Phase for Ongoing and Planned Trials
• 7.5 Trials with Virtual Components
• 7.6 Overview of Trials by Geography
• 7.7 Single-Country and Multinational Trials by Region
• 7.8 Top 20 Sponsors with Breakdown by Phase
• 7.9 Top 20 Sponsors with Breakdown by Status
• 7.10 Overview by Endpoint Status
• 7.11 Overview by Race and Ethnicity
• 7.12 Enrollment Data
• 7.13 Top 20 countries for Trial Sites
• 7.14 Top 20 Sites Globally
• 7.15 Feasibility Analysis - Geographic Overview
• 7.16 Feasibility Analysis - Benchmark Models

8 Deals Landscape

• 8.1 Mergers, Acquisitions, and Strategic Alliances by Region
• 8.2 Recent Mergers, Acquisitions, and Strategic Alliances

9 Commercial Assessment

• 9.1 Key Market Players

10 Future Market Catalysts

11 Appendix

• 11.1 Methodology
• 11.2 Methodology - Sales Forecast
• 11.3 Methodology - Pricing and Reimbursement
• 11.4 Methodology - PTSR and LoA Analysis
• 11.5 About the Authors
• 11.6 Contact Us
• 11.7 Disclaimer